Liquid Biopsy Markets by Cancer Type and Usage Type with Price and Volume Outlook, Forecasting and Analysis 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Liquid Biopsy Markets by Cancer Type and by Usage Type with Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report.

What is the impact of the COVID pandemic on the Liquid Biopsy market? We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market.

New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase.

The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview

2.1 Players in a Dynamic Market

2.1.1 Academic Research Lab

2.1.2 Diagnostic Test Developer

2.1.3 Genomic Instrumentation Supplier

2.1.3.1 Cell Separation and Viewing Instrumentation Supplier

2.1.4 Pharmaceutical/Reagent Supplier

2.1.5 Independent Testing Lab

2.1.6 Public National/regional lab

2.1.7 Hospital lab

2.1.8 Physician Lab

2.1.9 Audit Body

2.1.10 Certification Body

2.2 Using Biopsies

2.2.1 Cancer

2.2.2 Precancerous conditions

2.2.3 Inflammatory conditions

2.3 Biopsy Sites

2.4 The Situation Today – Biopsy Analysis

2.5 Evidence of Cancer – Liquid Biopsy Technology

2.5.1 The Big Picture on Liquid Biopsy Technology

2.5.2 The Role of CTCs

2.5.3 ctDNA – Going Mainstream?

2.5.4 Exosomes and Micro Vesicles – New Kid on the Block

2.5.5 The Multiple Play

2.6 Cancer Treatment Protocol Under Siege

2.6.1 Issues to Liquid Biopsy Adoption – Double Diagnostics

2.6.2 The Cancer Screening Market Opportunity

2.6.2.1 GRAIL – What Is It?

2.6.3 Cancer Management vs. Diagnosis

2.6.3.1 The Role of Risk Assessment

2.6.3.2 Managing Therapy

2.6.3.3 Monitoring Disease – What Is It?

2.6.4 Phases of Adoption – Looking into The Future

2.6.5 The Promise of Liquid Biopsy

2.7 Structure of Industry Plays a Part

2.7.1 Hospital Testing Share

2.7.2 Economies of Scale

2.7.2.1 Hospital vs. Central Lab

2.7.3 Physician Office Lab’s

2.7.4 Physician’s and POCT

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Non Invasive Game Changer

3.1.2 Lower Cost

3.1.3 Greater Accuracy

3.1.4 Wide Range of Potential Uses

3.1.5 Aging Population

3.2 Factors Limiting Growth

3.2.1 Lower prices

3.2.2 Lack of Standards

3.2.3 Protocol Resistance

3.2.4 Initial Adoption Cost

3.2.5 COVID-19

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution

3.4.2 Impact of NGS on pricing

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 CGES Testing, A Brave New World

3.4.5 Biochips/Giant Magnetoresistance based assay

4. Liquid Biopsy Recent Developments

4.1 Recent Developments – Importance and How to Use This Section

4.1.1 Importance of These Developments

5. Profiles of Key Players

6. The Global Market for Liquid Biopsy Diagnostics

6.1 Global Market Overview by Country

6.2 Global Market by Cancer – Overview

6.3 Global Market by Usage – Overview

7. Global Liquid Biopsy Diagnostic Markets – By Cancer

7.1 Breast

7.2 Colorectal

7.3 Cervical

7.4 Lung

7.5 Prostate

8. Global Liquid Biopsy Diagnostic Markets – by Usage

8.1 Screening

8.2 Diagnostic

8.3 Therapy

8.4 Monitor

Appendices

• United States Medicare System: 2021 Clinical Laboratory Fees Schedule

For more information about this report visit https://www.researchandmarkets.com/r/mqitxx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900